Compare ArcelorMittal SA (MT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs TransMedics Group Inc — how do they compare? ArcelorMittal SA trades at $64.24 (market cap $45.70B), while TransMedics Group Inc trades at $81.29 (market cap $2.74B). The key difference: ArcelorMittal SA is far larger — about 16.7× TransMedics Group Inc's market cap, and ArcelorMittal SA pays a 0.98% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and TransMedics Group Inc for 24 Days on average.
| MT | TMDX | |
|---|---|---|
Market Cap | $45.70B | $2.74B |
Volume | 1,964,621 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $150.42 |
52-Week Low | $36.91 | $61.99 |
Typical Hold Time | 36 Days | 24 Days |
Enterprise Value | $55.27B | $3.13B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $62.32, down 4.4% on the day, amid a bearish technical setup and recent operational disruptions in Ukraine. The stock shows mixed fundamentals with a low P/S of 0.75 and P/B of 0.84, but profitability metrics like net margin (2.88%) and ROE (3.32%) remain modest. Recent Q2 2026 earnings missed estimates, though Q1 and Q4 2025 beat expectations. Analyst consensus is bullish with a $74.33 price target, but technical indicators signal caution.
The outlook is clouded by near-term headwinds including the Ukraine plant impairment and volatile steel demand, yet long-term value is supported by low valuation multiples and strategic regionalization efforts. Risks include geopolitical exposure and cyclical industry pressures, but institutional sentiment remains positive with 52% buy ratings.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
